S

Shenzhen Salubris Pharmaceuticals Co Ltd
SZSE:002294

Watchlist Manager
Shenzhen Salubris Pharmaceuticals Co Ltd
SZSE:002294
Watchlist
Price: 58.7 CNY -0.83% Market Closed
Market Cap: 65.4B CNY

Operating Margin
Shenzhen Salubris Pharmaceuticals Co Ltd

14.9%
Current
16%
Average
6.1%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
14.9%
=
Operating Profit
632.7m
/
Revenue
4.3B

Operating Margin Across Competitors

No Stocks Found

Shenzhen Salubris Pharmaceuticals Co Ltd
Glance View

Market Cap
65.4B CNY
Industry
Pharmaceuticals

Shenzhen Salubris Pharmaceuticals Co., Ltd. stands as a dynamic player in the pharmaceutical landscape, tracing its origins to China’s bustling hub of innovation, Shenzhen. From its inception, Salubris has steadily cultivated a robust portfolio, deeply rooted in the development, production, and commercialization of a wide array of pharmaceutical products. With a steadfast focus on cardiovascular and cerebrovascular medications, the company has adeptly positioned itself to meet significant medical needs, leveraging its expertise to produce both traditional and novel therapies. This focus is complemented by an ambitious expansion into biopharmaceuticals, a sector that holds significant potential for growth. Salubris thrives by combining its innovative R&D capabilities with efficient production processes, ensuring that its offerings not only reach a broad customer base but also adhere to stringent quality standards. The company’s business model revolves around a meticulously crafted combination of research innovation and strategic partnerships. By investing significantly in research and development, Salubris ensures a pipeline filled with promising drugs poised to address prevalent health issues. The company maximizes its revenues through its sales network, which extends beyond domestic borders, tapping into international markets where demand for high-quality pharmaceuticals continues to rise. Additionally, Salubris has been proactive in pursuing collaborations and partnerships, both to bolster its research capabilities and to navigate regulatory landscapes more effectively. By marrying these strategic approaches, Salubris not only sustains its competitive edge but also ensures a steady growth trajectory, embodying a business narrative that resonates with resilience and forward-thinking ambition.

Intrinsic Value
26.08 CNY
Overvaluation 56%
Intrinsic Value
Price
S
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
14.9%
=
Operating Profit
632.7m
/
Revenue
4.3B
What is the Operating Margin of Shenzhen Salubris Pharmaceuticals Co Ltd?

Based on Shenzhen Salubris Pharmaceuticals Co Ltd's most recent financial statements, the company has Operating Margin of 14.9%.

Back to Top